Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

The build vs. outsource decision is strategic. Building in-house is justified when manufacturing is a core competitive advantage or the process itself is your key IP. Otherwise, outsourcing to a CDMO offers critical speed to clinic and preserves capital.

The sterile fill market isn't monolithic; it's segmented by manufacturing type. High-volume, low-mix products like GLP-1s require different CDMO capabilities than high-mix, lower-volume biologics. The latter demands deep expertise in tech transfer and new product launches, a distinct skill set from routine, high-scale production.

A contract development and manufacturing organization (CDMO) that began as a sponsor company developing its own drugs possesses a unique understanding of the entire asset lifecycle. This "sponsor DNA" enables them to provide more strategic, consultative guidance beyond simply fulfilling a manufacturing contract.

In the CRO market, negotiation leverage comes not from size, but from deep expertise and a proven track record with regulators. Biotech and pharma clients prioritize specialized partnership in specific domains (e.g., cell therapy) over a supplier's sheer capacity or lower pricing.

The CDMO market is segmenting, rewarding companies that specialize in complex niches like sterile filling. Rather than trying to do everything, focusing on being a world-class expert attracts clients who need specialized services, much like a patient chooses a heart surgeon over a general pharmacy for a critical procedure.

The true constraint in scaling sterile fill manufacturing is the availability of skilled personnel, not the equipment. The expertise required for compliance and product launches is harder to acquire than capital assets. This makes proactive, long-term hiring and training a critical competitive advantage for growth.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.